製品の概要

  • 製品名Lanreotide peptide

製品の詳細

  • 由来Synthetic

特性

Our Abpromise guarantee covers the use of ab73337 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • アプリケーション

    SDS-PAGE

  • 精製度> 95 % SDS-PAGE.
    Purity is greater than 99.0% as determined by RP-HPLC and SDS-PAGE.
  • 製品の状態Lyophilised
  • 備考For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

    Preservative: None
    Constituents: Mannitol, Tween 80

  • 再構成Reconstitute in sterile 18MOhm/cm H2O at not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

関連情報

  • 別名
    • Somatuline
  • 関連性Lanreotide is a a synthetic cyclic octapeptide used as a drug in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. Lanreotide is a synthetic analogue of somatostatin, a naturally occurring inhibitory hormone which blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Lanreotide binds to the same receptors as somatostatin, although with higher affinity to peripheral receptors, and has similar activity. However, while somatostatin is quickly broken down in the body (within minutes), lanreotide has a much longer half-life, and produces far more prolonged effects.

Lanreotide peptide (ab73337) 使用論文

ab73337 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab73337.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"